Immunization News and Research

RSS

How do immunocompromised patients respond to COVID-19 vaccines?

The COVID-19 vaccines produce a boost in antibody activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, new research suggests vaccine responses aren’t all created equal. Their findings showed that immunocompromised patients, such as transplant recipients, with no prior exposure to SARS-CoV-2 produce little to no neutralizing antibodies.

18 Jul 2021

Study provides insights into vaccine acceptance and hesitancy in low- and-middle income countries

New research published in Nature Medicine reveals willingness to get a COVID-19 vaccine was considerably higher in developing countries (80% of respondents) than in the United States (65%) and Russia (30%).

16 Jul 2021

India's Mission Indradhanush improves vaccination outcomes for children

Researchers at CDDEP recently published 'Improving vaccination coverage and timeliness through periodic intensification of routine immunization: evidence from Mission Indradhanush' where they evaluated the performance of India's Mission Indradhanush (MI) child vaccination campaign -- a periodic intensification of the routine immunization program.

16 Jul 2021

Mixing COVID vaccines generates a comparable immune response

The validity and safety of mixing first and second doses of different types are explored in a paper recently uploaded to the preprint server medRxiv* by Rose et al. (July 13th, 2021), finding that robust antibody response is induced, comparable to, and perhaps even exceed that generated by homologous dosing.

16 Jul 2021

23 million children missed out on basic vaccines in 2020 due to COVID-19, new data shows

23 million children missed out on basic vaccines through routine immunization services in 2020 – 3.7 million more than in 2019 - according to official data published today by WHO and UNICEF.

15 Jul 2021

New OMV-based COVID-19 vaccine candidate proves effective in mice

Researchers in Italy have demonstrated the efficacy of using modified outer membrane vesicles (OMVs) as a vaccine to protect against coronavirus disease 2019 (COVID-19) in an animal model.

14 Jul 2021

Red state, blue state, twin outbreak: Behind Wyoming and Colorado’s anomalous covid spikes

Brandon Graves said covid-19 arrived in Wheatland the way new movies do in this High Plains farming town: months after hitting the big cities and without much fanfare.

14 Jul 2021

“React and inject”: synthetic peptide-modified nanodiamonds as emergency pan-coronavirus vaccines

A recent study published in the MDPI journal, Pathogens, describes a coronavirus peptide vaccine antigen in the form of nanodiamond-based formulations, that demonstrated a robust and long-lasting immune response. The nanodiamonds proved to be a powerful and versatile platform for antigen conjugation. This could make it a safe and effective strategy for the production of off-the-shelf vaccines against multiple coronaviruses.

13 Jul 2021

Real-world evidence SARS-CoV-2 mRNA vaccines work and help prevent worst outcomes

Researchers in the United States have conducted a study demonstrating the real-world effectiveness of the Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273 vaccines at preventing hospitalizations due to coronavirus disease 2019 (COVID-19).

12 Jul 2021

mRNA-based COVID-19 vaccine CV07050101 demonstrates limited immunogenicity in non-human primates

Scientists from the US and Germany have recently evaluated the efficacy of an mRNA-based COVID-19 vaccine candidate, CV07050101, in inducing humoral and cellular immune responses in non-human primates. The study reveals that prime-boost immunization with the vaccine candidate induces only limited immunity against SARS-CoV-2.

12 Jul 2021

Pfizer-BioNTech’s COVID-19 vaccine effective and safe for use among cancer patients

Researchers in Israel have conducted a study showing that the use of Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine appears to be safe and effective among patients with cancer.

11 Jul 2021

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

A recent study by a team of scientists at Beth Israel Deaconess Medical Center and Janssen Vaccines & Prevention has demonstrated that humoral and cellular immunity elicited by the coronavirus disease 2019 (COVID-19) vaccine Ad26.COV2.S remains active for at least eight months.

9 Jul 2021

Using commensal bacteria to produce vaccine-like immune responses to dangerous bacterium

Researchers have produced vaccine-like immune responses to a dangerous bacterium by colonizing 26 healthy volunteers with a related, but harmless, commensal bacterial species. The first-in-human, controlled infection study showed the strategy was safe, as no side effects were reported and the volunteers didn't transmit the commensal bacteria to bedroom-sharers over the 90-day study.

8 Jul 2021

Striking increase in SARS-CoV-2 antibodies seen with prime dose AstraZeneca vaccine followed by Pfizer-BioNTech

Researchers in Germany have provided evidence that a booster shot of a messenger RNA (mRNA)-based coronavirus disease 2019 (COVID-19) vaccine following prime immunization with AstraZeneca’s adenoviral vector-based vaccine is sufficient to achieve high levels of neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Jul 2021

Changes to COVID-19 vaccination strategy could speed up herd immunity

Researchers in the United States have proposed changes to the current coronavirus disease 2019 (COVID-19) vaccination strategy that they say would increase the likelihood of herd immunity being achieved in the most timely and cost-effective manner.

8 Jul 2021

New biological pathway selectively controls how key immune cells mature into functional components

Immunologists at St. Jude Children's Research Hospital have identified a biological pathway that selectively controls how key immune cells, called T follicular helper cells, mature into functional components of the immune system.

8 Jul 2021

New study reports low SARS-CoV-2 breakthrough infections in vaccinated healthcare workers

Researchers examined cases of SARS-CoV-2 infection in fully and partially vaccinated healthcare workers, finding that vaccination provided strong immunity to the virus even though VOCs are on the rise in the non-vaccinated community at large.

7 Jul 2021

Will the US’s COVID-19 vaccination campaign be undermined by novel SARS-CoV-2 variants of concern?

New research from Arizona State University, USA, uses a novel mathematical model to predict the impact of vaccination and vaccine-induced cross-protection on the B.1.1.7 variant and other SARS-CoV-2 variants circulating in the US as of June 2021. The study has been published in medRxiv* preprint server, while it undergoes peer review.

7 Jul 2021

COVID-19 vaccination may be stemming evolution of “fitter” SARS-CoV-2 variants

Researchers in the United States and India have presented the first known evidence that the rollout of coronavirus disease 2019 (COVID-19) vaccination is restricting the evolutionary and immune escape pathways accessible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

6 Jul 2021

Moderna’s COVID-19 vaccine elicits durable T cell memory and antibody responses

Researchers in the United States have shown that Moderna’s mRNA-1273 coronavirus disease 2019 (COVID-19) vaccine induces durable antibody and T cell responses to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are comparable to those seen in cases of COVID-19 caused by natural SARS-CoV-2 infection.

6 Jul 2021

Immunization News and Research

How do immunocompromised patients respond to COVID-19 vaccines?

Study provides insights into vaccine acceptance and hesitancy in low- and-middle income countries

India's Mission Indradhanush improves vaccination outcomes for children

Mixing COVID vaccines generates a comparable immune response

23 million children missed out on basic vaccines in 2020 due to COVID-19, new data shows

New OMV-based COVID-19 vaccine candidate proves effective in mice

Red state, blue state, twin outbreak: Behind Wyoming and Colorado’s anomalous covid spikes

“React and inject”: synthetic peptide-modified nanodiamonds as emergency pan-coronavirus vaccines

Real-world evidence SARS-CoV-2 mRNA vaccines work and help prevent worst outcomes

mRNA-based COVID-19 vaccine CV07050101 demonstrates limited immunogenicity in non-human primates

Pfizer-BioNTech’s COVID-19 vaccine effective and safe for use among cancer patients

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

Using commensal bacteria to produce vaccine-like immune responses to dangerous bacterium

Striking increase in SARS-CoV-2 antibodies seen with prime dose AstraZeneca vaccine followed by Pfizer-BioNTech

Changes to COVID-19 vaccination strategy could speed up herd immunity

New biological pathway selectively controls how key immune cells mature into functional components

New study reports low SARS-CoV-2 breakthrough infections in vaccinated healthcare workers

Will the US’s COVID-19 vaccination campaign be undermined by novel SARS-CoV-2 variants of concern?

COVID-19 vaccination may be stemming evolution of “fitter” SARS-CoV-2 variants

Moderna’s COVID-19 vaccine elicits durable T cell memory and antibody responses

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News